Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Photocure ASA ( (PHCUF) ) is now available.
Photocure’s partner Asieris Pharmaceuticals has secured a Drug Registration Certificate from China’s National Medical Products Administration for APL-1702, marketed as Cevira, paving the way for its commercial launch as a non-surgical treatment for high-grade squamous intraepithelial lesions. The approval triggers milestone eligibility for Photocure and positions Cevira as the first non-invasive therapy for certain cervical precancerous lesions, potentially reshaping a market historically dominated by surgical interventions.
Developed by Photocure and out-licensed to Asieris in 2019, Cevira is a photodynamic drug-device combination that achieved its primary endpoint in a Phase III trial in 2023 and is now under review in Europe, with U.S. Phase III plans agreed with regulators. The Chinese authorization reinforces Photocure’s strategy of leveraging its photodynamic technology beyond bladder cancer, broadening its revenue prospects and strengthening its role in organ-sparing, minimally invasive cancer care.
More about Photocure ASA
Photocure ASA, headquartered in Oslo and listed on the Oslo Stock Exchange, is a specialty pharmaceutical company known as The Bladder Cancer Company, focused on photodynamic technologies that make cancer cells glow to improve diagnosis and treatment. Its portfolio centers on transformative, minimally invasive solutions for urologic oncology, developed in-house and often commercialized through global licensing partnerships.
Average Trading Volume: 58,705
Current Market Cap: NOK1.71B
For a thorough assessment of PHCUF stock, go to TipRanks’ Stock Analysis page.